Related Experiment Video
Updated: Jul 19, 2025

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Abstract:
A novel study design comparing results from a phase II trial with those from a prior phase III trial shows that a daratumumab-based regimen is more effective in ultra-high-risk melanoma than a conventional drug combination. However, it is unclear whether this approach can be applied to other contexts and forms of cancer.
More Related Videos
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
10:04Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
Related Concept Videos
Treatment Resistant Cancers
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...